Journal raises concern about blood-thinning drug

A medical journal raised concerns Wednesday about a blood-thinning drug widely used by people at risk of stroke, accusing its manufacturer of concealing safety data and regulators of laxness.

A key selling point of the known as dabigatran or Pradaxa was that it required no blood-level monitoring, as does competitor warfarin.

Dabigatran's maker, Boehringer Ingelheim, had said the drug was better than warfarin at reducing stroke in people with , with a similar risk of major bleeds, according to the British Medical Journal (BMJ).

Based on its own probe, the journal accused Boehringer of concealing information that blood-level monitoring could in fact reduce major bleeds by up to 30-40 percent compared to warfarin.

"The BMJ has found that neither doctors nor regulators have ever been aware of these calculations," said a statement.

Irregular heart rhythm (atrial fibrillation) affects about 800,000 Britons and over three million Americans.

According to BMJ investigations editor Deborah Cohen, who conducted the research, millions of people take the anti-clotting drug, with blood levels found to vary greatly between patients.

"These analyses suggest that dabigatran could be made safer," she told AFP by email.

A one-off test may be sufficient to check how a particular patient was reacting to the drug, which seeks to keep the blood thin enough to protect against stroke, but not so thin to pose a major bleed risk.

The BMJ said the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), in 2010 and 2011 respectively, approved the drug without the need for blood tests, despite concerns.

"Once licensed, dabigatran proved a financial success, but by the end of 2011 concerns about fatal bleeds were beginning to emerge," it wrote.

In May, the manufacturer settled for $650 million (480 million euros) in 4,000 cases in the United States linked to use of its blood-thinner.

The FDA told AFP its approval of the drug had been based on information supplied by Boehringer.

"The FDA is constantly examining product labelling to make sure the label reflects the current knowledge with regard to the benefits and risks of the product," the agency said, adding it had published "several" drug safety tips about Pradaxa over the years.

The EMA said it was evaluating whether any relevant information had not been submitted.

"In case of any new evidence, the EMA will take action as necessary to guarantee the safety of patients," it said.

Boehringer UK in a tweet advised patients not to stop taking the drug, but consult their doctor if they were concerned.

"We remain confident in our medicine's benefits and safety profile which have been reaffirmed by the European Medicines Agency (EMA), the US Food and Drug Administration (FDA) and others," it tweeted.

add to favorites email to friend print save as pdf

Related Stories

Anti-clot drug recommended for new approval in EU

Sep 21, 2012

(AP)—Advisers to European Union regulators have recommended approval of a new anti-clotting drug for use by adults with a common irregular heart rhythm that boosts risk of strokes or blood clots, drugmakers Bristol-Myers ...

French families file suit over alleged blood-thinner deaths

Oct 09, 2013

The families of four elderly people who died while taking an anti-clotting drug have filed a legal complaint against France's drugs safety body and Germany-based drugmaker Boehringer Ingelheim, their lawyers said Wednesday.

Recommended for you

US approves new, hard-to-abuse hydrocodone pill (Update)

7 hours ago

U.S. government health regulators on Thursday approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking ...

Soaring generic drug prices draw Senate scrutiny

11 hours ago

Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington ...

Only half of patients take their medications as prescribed

21 hours ago

The cost of patients not taking their medications as prescribed can be substantial in terms of their health. Although a large amount of research evidence has tried to address this problem, there are no well-established ...

Interpol call for roadmap to tackle fake drugs

Nov 19, 2014

Interpol on Wednesday called for a greater global response to pharmaceutical crime as it warned criminal gangs were capitalising on weaknesses in legislation and border controls.

Empagliflozin in type 2 diabetes: Added benefit not proven

Nov 19, 2014

Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. The German Institute for Quality and ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.